Literature DB >> 27609205

Drug use in persons with and without Alzheimer's disease aged 90 years or more.

Heidi Taipale1,2,3, Marjaana Koponen1,2, Antti Tanskanen3,4,5, Anna-Maija Tolppanen2,6, Jari Tiihonen3,4, Sirpa Hartikainen1,2.   

Abstract

BACKGROUND: increasing number of persons reach very high age but few studies have investigated their drug use patterns.
OBJECTIVE: to compare drug use among persons with Alzheimer's disease (AD) aged ≥90 years to persons without AD with similar age and to younger persons with AD.
DESIGN: register-based data were from the MEDALZ cohort including all community-dwelling persons diagnosed with AD 2005-11 in Finland. They were identified from Special Reimbursement register. One comparison person without AD was matched with age-, gender- and region of residence. Persons with AD were divided to those aged ≥90 years (N = 3,319) and <90 years (N = 63,896) at the time of AD diagnoses. Drug use was analysed during a 6-month period after AD diagnosis. Logistic regression models were constructed to compare prevalence of drug use.
RESULTS: compared to comparison persons without AD with similar age, persons with AD aged ≥90 years were more likely to use antipsychotics (comorbidity adjusted odds ratio [aOR] 4.84, 95% CI 4.07-5.75; CI, confidence intervals) and antidepressants (aOR 2.45, 95% CI 2.14-2.80). In addition, persons with AD used more likely preventive drugs such as statins (aOR 1.20, 95% CI 1.04-1.38) and bisphosphonates (aOR 1.33, 95% CI 1.13-1.57). Compared to younger persons with AD, those aged ≥90 years were more likely to use psychotropic drugs (55.6% vs. 48.4%, aOR 1.30, 95% CI 1.21-1.39), including antipsychotics (aOR 1.40, 95% CI 1.28-1.52) and BZDRs (aOR 1.34, 95% CI 1.25-1.45).
CONCLUSIONS: the vulnerable oldest persons with AD receive a substantial burden of psychotropics.
© The Author 2016. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer's disease; drug utilisation; nonagenarian; older people; psychotropic drugs

Mesh:

Substances:

Year:  2016        PMID: 27609205     DOI: 10.1093/ageing/afw141

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  5 in total

1.  How Common is Statin Use in the Oldest Old?

Authors:  Wade Thompson; Anton Pottegård; Jesper Bo Nielsen; Peter Haastrup; Dorte Ejg Jarbøl
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

2.  Neuroprotective Potency of Neolignans in Magnolia officinalis Cortex Against Brain Disorders.

Authors:  Shun Zhu; Fang Liu; Ruiyuan Zhang; Zongxiang Xiong; Qian Zhang; Li Hao; Shiyin Chen
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

3.  The composition of polypharmacy: A register-based study of Swedes aged 75 years and older.

Authors:  Jonas W Wastesson; Angel Cedazo Minguez; Johan Fastbom; Silvia Maioli; Kristina Johnell
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

Review 4.  Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease.

Authors:  Ramón Cacabelos; Arun Meyyazhagan; Juan C Carril; Pablo Cacabelos; Óscar Teijido
Journal:  J Pers Med       Date:  2018-01-03

5.  "Text It" program to track falls in patients with Alzheimer's disease and dementia.

Authors:  Rebecca J Kamil; Dara Bakar; Matthew Ehrenburg; Scott Frankenthaler; Eric X Wei; Eric Anson; Esther Oh; Yuri Agrawal
Journal:  Alzheimers Dement (N Y)       Date:  2018-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.